These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15577635)

  • 1. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
    Valer L; Martín-Carbonero L; de Mendoza C; Corral A; Soriano V
    AIDS; 2004 Oct; 18(15):2094-6. PubMed ID: 15577635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1.
    Segondy M; Montes B
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):110-1. PubMed ID: 15608534
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
    Theys K; Vercauteren J; Snoeck J; Zazzi M; Camacho RJ; Torti C; Schülter E; Clotet B; Sönnerborg A; De Luca A; Grossman Z; Struck D; Vandamme AM; Abecasis AB
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1053-6. PubMed ID: 23183438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy.
    Lo Cicero M; Bulgheroni E; Soster F; Viganò O; Cicconi P; Galli M; Rusconi S
    J Acquir Immune Defic Syndr; 2005 Oct; 40(2):238-41. PubMed ID: 16186745
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
    Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM; Bacheler L; Koontz D; Mellors JW
    J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
    McColl DJ; Margot NA; Wulfsohn M; Coakley DF; Cheng AK; Miller MD
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1340-50. PubMed ID: 15483463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
    Svarovskaia ES; Margot NA; Bae AS; Waters JM; Goodman D; Zhong L; Borroto-Esoda K; Miller MD
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):174-80. PubMed ID: 17667333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM; Merigan TC; Winters MA; Heseltine PN
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
    Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
    Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    Margot NA; Wong P; Kulkarni R; White K; Porter D; Abram ME; Callebaut C; Miller MD
    J Infect Dis; 2017 Mar; 215(6):920-927. PubMed ID: 28453836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K65R, TAMs and tenofovir.
    Miller MD
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
    Sluis-Cremer N; Moore K; Radzio J; Sonza S; Tachedjian G
    AIDS; 2010 Jan; 24(2):317-9. PubMed ID: 20010074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
    Ruane PJ; Luber AD
    MedGenMed; 2004 Apr; 6(2):31. PubMed ID: 15266257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
    Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M
    J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
    Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
    Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
    Pingen M; Nijhuis M; Mudrikova T; van Laarhoven A; Langebeek N; Richter C; Boucher CA; Wensing AM
    J Antimicrob Chemother; 2015 Feb; 70(2):573-80. PubMed ID: 25261422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.